CSPC Group announced that SYS6037 injection, a Class 1 new prophylactic biological product developed by the Group in cooperation with the Institute of Microbiology of the Chinese Academy of Sciences, has been approved by the US Food and Drug Administration and can conduct clinical trials in the US. Preclinical studies have shown that compared to live attenuated vaccines, this product has better immunogenicity and protective efficacy, and shows a broad spectrum of cross-reactions to various orthopedics virus antigens.

CSPC Group announced that SYS6037 injection, a Class 1 new prophylactic biological product developed by the Group in cooperation with the Institute of Microbiology of the Chinese Academy of Sciences, has been approved by the US Food and Drug Administration and can conduct clinical trials in the US. Preclinical studies have shown that compared to live attenuated vaccines, this product has better immunogenicity and protective efficacy, and shows a broad spectrum of cross-reactions to various orthopedics virus antigens.